These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
413 related articles for article (PubMed ID: 16048908)
1. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Zhang D; Tai LK; Wong LL; Chiu LL; Sethi SK; Koay ES Mol Cell Proteomics; 2005 Nov; 4(11):1686-96. PubMed ID: 16048908 [TBL] [Abstract][Full Text] [Related]
2. Phosphorylation of Ser78 of Hsp27 correlated with HER-2/neu status and lymph node positivity in breast cancer. Zhang D; Wong LL; Koay ES Mol Cancer; 2007 Aug; 6():52. PubMed ID: 17697330 [TBL] [Abstract][Full Text] [Related]
3. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors. Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149 [TBL] [Abstract][Full Text] [Related]
4. 17beta-hydroxysteroid dehydrogenase type 5 is negatively correlated to apoptosis inhibitor GRP78 and tumor-secreted protein PGK1, and modulates breast cancer cell viability and proliferation. Xu D; Aka JA; Wang R; Lin SX J Steroid Biochem Mol Biol; 2017 Jul; 171():270-280. PubMed ID: 28457968 [TBL] [Abstract][Full Text] [Related]
5. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Menendez JA; Vellon L; Lupu R Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499 [TBL] [Abstract][Full Text] [Related]
6. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification. Menendez JA; Vellon L; Colomer R; Lupu R Ann Oncol; 2005 Mar; 16(3):359-71. PubMed ID: 15642702 [TBL] [Abstract][Full Text] [Related]
7. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes. Menendez JA; Vellon L; Lupu R Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011 [TBL] [Abstract][Full Text] [Related]
8. Proteome analysis of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR. Yang YX; Xiao ZQ; Chen ZC; Zhang GY; Yi H; Zhang PF; Li JL; Zhu G Proteomics; 2006 Mar; 6(6):2009-21. PubMed ID: 16525997 [TBL] [Abstract][Full Text] [Related]
9. Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability. Lam PB; Burga LN; Wu BP; Hofstatter EW; Lu KP; Wulf GM Mol Cancer; 2008 Dec; 7():91. PubMed ID: 19077306 [TBL] [Abstract][Full Text] [Related]
10. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells. Baumann J; Wong J; Sun Y; Conklin DS BMC Cancer; 2016 Jul; 16():551. PubMed ID: 27464732 [TBL] [Abstract][Full Text] [Related]
11. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies. Singer CF; Köstler WJ; Hudelist G Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208 [TBL] [Abstract][Full Text] [Related]
12. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Hudelist G; Köstler WJ; Czerwenka K; Kubista E; Attems J; Müller R; Gschwantler-Kaulich D; Manavi M; Huber I; Hoschützky H; Zielinski CC; Singer CF Int J Cancer; 2006 Mar; 118(5):1126-34. PubMed ID: 16161043 [TBL] [Abstract][Full Text] [Related]
13. Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Luk JM; Lam CT; Siu AF; Lam BY; Ng IO; Hu MY; Che CM; Fan ST Proteomics; 2006 Feb; 6(3):1049-57. PubMed ID: 16400691 [TBL] [Abstract][Full Text] [Related]
14. Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade. Fonseca-Sánchez MA; Rodríguez Cuevas S; Mendoza-Hernández G; Bautista-Piña V; Arechaga Ocampo E; Hidalgo Miranda A; Quintanar Jurado V; Marchat LA; Alvarez-Sánchez E; Pérez Plasencia C; López-Camarillo C Int J Oncol; 2012 Aug; 41(2):670-80. PubMed ID: 22614840 [TBL] [Abstract][Full Text] [Related]
15. HER-2/neu expression in primary and metastatic breast cancer. Lower EE; Glass E; Blau R; Harman S Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700 [TBL] [Abstract][Full Text] [Related]
16. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Menendez JA; Vellon L; Lupu R Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086 [TBL] [Abstract][Full Text] [Related]
17. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. Simon R; Nocito A; Hübscher T; Bucher C; Torhorst J; Schraml P; Bubendorf L; Mihatsch MM; Moch H; Wilber K; Schötzau A; Kononen J; Sauter G J Natl Cancer Inst; 2001 Aug; 93(15):1141-6. PubMed ID: 11481385 [TBL] [Abstract][Full Text] [Related]
18. Secretomic and proteomic analysis of potential breast cancer markers by two-dimensional differential gel electrophoresis. Lai TC; Chou HC; Chen YW; Lee TR; Chan HT; Shen HH; Lee WT; Lin ST; Lu YC; Wu CL; Chan HL J Proteome Res; 2010 Mar; 9(3):1302-22. PubMed ID: 20052998 [TBL] [Abstract][Full Text] [Related]
19. Proteome analysis of gastric cancer metastasis by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of metastasis-related proteins. Chen J; Kähne T; Röcken C; Götze T; Yu J; Sung JJ; Chen M; Hu P; Malfertheiner P; Ebert MP J Proteome Res; 2004; 3(5):1009-16. PubMed ID: 15473690 [TBL] [Abstract][Full Text] [Related]
20. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Emens LA Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]